References
- Aston BC. (1923). The poisonous, suspected and medicinal plants of New Zealand. New Zeal J Agric 26:78–80
- Aveyard P, West R. (2013). Cytisine and the failure to market and regulate for human health. Thorax 68:989
- Borland R, Yong HH, O’Connor RJ, et al. (2010). The reliability and predictive validity of the Heaviness of Smoking Index and its two components: findings from the International Tobacco Control Four Country study. Nicotine Tob Res 12:S45–50
- Burstein AH, Fullerton T, Clark DJ, Faessel HM. (2006). Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. J Clin Pharmacol 46:1234–40
- Clinch PG, Palmer-Jones T, Forster IW. (1972). Effect on honey bees of nectar from the yellow kowhai (Sophora microphylla Ait.). New Zeal J Agric Res 15:194–201
- Etter JF. (2006). Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 166:1553–9
- Faessel HM, Smith BJ, Gibbs MA, et al. (2006). Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J Clin Pharmacol 46:991–8
- Hughes JR. (2007). Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 9:315–27
- Jeong SH, Newcombe D, Sheridan J, Tingle M. (2015). Pharmacokinetics of cytisine, an alpha4 beta2 nicotinic receptor partial agonist, in healthy smokers following a single dose. Drug Test Anal 7:475–82
- Musshoff F, Madea B. (2009). Fatal cytisine intoxication and analysis of biological samples with LC-MS/MS. Forensic Sci Int 186:e1–4
- Prochaska JJ, Das S, Benowitz NL. (2013). Cytisine, the world’s oldest smoking cessation aid. BMJ 347:f5198
- Rhys J. (2007). Rongoā – medicinal use of plants. [online]. http://www.TeAra.govt.nz/en/rongoa-medicinal-use-of-plants [Accessed Date 2017]
- Richards HG, Stephens A. (1970). A fatal case of laburnum seed poisoning. Med Sci Law 10:260–6
- Rollema H, Coe JW, Chambers LK, et al. (2007). Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 28:316–25
- Stoyanov S, Yanachkova M. (1972). Tabex–therapeutic efficacy and tolerance. Savr Med 23:6
- Tutka P, Zatonski W. (2006). Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol Rep 58:777–98
- Vinnikov D, Brimkulov N, Burjubaeva A. (2008). A double-blind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers. J Smok Cessat 3:57–62
- Walker N, Bullen C, Barnes J, et al. (2016). Getting cytisine licensed for use world-wide: a call to action. Addiction 111:1895–8
- Walker N, Howe C, Glover M, et al. (2014). Cytisine versus nicotine for smoking cessation. N Engl J Med 371:2353–62
- West R, Zatonski W, Cedzynska M, et al. (2011). Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 365:1193–200